keyword
MENU ▼
Read by QxMD icon Read
search

Dyskinesia anxiety

keyword
https://www.readbyqxmd.com/read/28446646/randomized-controlled-trial-of-deutetrabenazine-for-tardive-dyskinesia-the-arm-td-study
#1
RANDOMIZED CONTROLLED TRIAL
Hubert H Fernandez, Stewart A Factor, Robert A Hauser, Joohi Jimenez-Shahed, William G Ondo, L Fredrik Jarskog, Herbert Y Meltzer, Scott W Woods, Danny Bega, Mark S LeDoux, David R Shprecher, Charles Davis, Mat D Davis, David Stamler, Karen E Anderson
OBJECTIVE: To determine the efficacy and safety of deutetrabenazine as a treatment for tardive dyskinesia (TD). METHODS: One hundred seventeen patients with moderate to severe TD received deutetrabenazine or placebo in this randomized, double-blind, multicenter trial. Eligibility criteria included an Abnormal Involuntary Movement Scale (AIMS) score of ≥6 assessed by blinded central video rating, stable psychiatric illness, and stable psychoactive medication treatment...
May 23, 2017: Neurology
https://www.readbyqxmd.com/read/28379218/further-pharmacological-characterization-of-eltoprazine-focus-on-its-anxiolytic-anorexic-and-adverse%C3%A2-effect-potential
#2
Andreas Gravius, Andrzej Dekundy, Anita Vanaga, Lutz Franke, Wojciech Danysz
Eltoprazine, a drug that had previously been developed for aggression, has recently been investigated for L-DOPA-induced dyskinesia in animal models of Parkinson´s disease (PD) and in dyskinetic PD patients. Much less is known about effects of eltoprazine in other therapeutic indications. Indeed, the pharmacological profile of eltoprazine might suggest its effects on anxiety and food intake, but also adverse effect potential, which is the focus of the present study. Given for 2 weeks either as infusion or as twice-daily treatment, eltoprazine produced a decrease in food intake and body weight at doses leading to 200-500 nM plasma concentrations...
2017: Acta Neurobiologiae Experimentalis
https://www.readbyqxmd.com/read/28377723/multiple-psychopharmacological-effects-of-the-traditional-japanese-kampo-medicine-yokukansan-and-the-brain-regions-it-affects
#3
REVIEW
Kazushige Mizoguchi, Yasushi Ikarashi
Yokukansan (YKS), a traditional Japanese Kampo medicine, has indications for use in night crying and irritability in children, as well as neurosis and insomnia. It is currently also used for the remedy of the behavioral and psychological symptoms of dementia (BPSD), such as aggressiveness, agitation, and hallucinations. In parallel with clinical evidence, a significant amount of fundamental researches have been undertaken to clarify the neuropsychopharmacological efficacies of YKS, with approximately 70 articles, including our own, being published to date...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/28374238/antioxidant-effects-of-rice-bran-oil-mitigate-repeated-haloperidol-induced-tardive-dyskinesia-in-male-rats
#4
Noreen Samad, Darakhshan Jabeen Haleem
Tardive dyskinesia (TD) is associated with the use of antipsychotic drugs such as D2 antagonist haloperidol (HP). The chronic use of HP is involved in the causation of free radicals and/or oxidative stress. In view of the nootropic, anti-anxiety, anti-inflammatory-like effects of rice bran oil (RBO) in a variety of investigations, we assessed the protective properties of RBO on HP-induced TD and neurochemical alteration. Rats treated with HP orally at a dose of 0.2 mg/kg/day for a period of 5 weeks developed VCMs which increased progressively as the treatment continued for 5 weeks...
August 2017: Metabolic Brain Disease
https://www.readbyqxmd.com/read/28361274/the-patient-s-experience-of-primary-ciliary-dyskinesia-a-systematic-review
#5
REVIEW
Laura Behan, Bruna Rubbo, Jane S Lucas, Audrey Dunn Galvin
BACKGROUND: Primary ciliary dyskinesia (PCD) is a rare genetic disorder characterised by progressive sinopulmonary disease, with symptoms starting soon after birth. The aim of this study is to critically review, analyse, and synthesise the literature in order to understand the experiences of patients with primary ciliary dyskinesia (PCD) and the impact on health-related quality of life. METHOD: MEDLINE, EBSCO, Cumulative Index to Nursing and Allied Health Literature (CINAHL), PsycINFO and EMBASE were searched according to the inclusion criteria...
March 30, 2017: Quality of Life Research
https://www.readbyqxmd.com/read/28027109/the-relationship-between-early-haloperidol-response-and-associated-extrapyramidal-side-effects
#6
Sean A Rasmussen, Patricia I Rosebush, Michael F Mazurek
BACKGROUND: Early response to antipsychotic medication within 2 weeks of initiating treatment can predict psychiatric outcomes. However, it is unclear whether early response is also predictive of extrapyramidal side effects (EPSs) associated with antipsychotic medications. METHODS: In this study, we investigated 136 consecutive antipsychotic-naive, first-episode psychosis patients naturalistically treated with haloperidol. Patients were assessed at baseline and weekly after treatment initiation using the Brief Psychiatric Rating Scale, Hamilton Depression Rating Scale, and Hamilton Anxiety Rating Scale...
February 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/27989846/cortical-areas-involved-in-behavioral-expression-of-external-pallidum-dysfunctions-a-pet-imaging-study-in-non-human-primates
#7
Laurent Galineau, Aurélie Kas, Yulia Worbe, Marion Chaigneau, Anne-Sophie Herard, Martine Guillermier, Thierry Delzescaux, Jean Féger, Philippe Hantraye, Léon Tremblay
The external pallidum (GPe) is a component of the indirect pathway centrally placed in the basal ganglia. Studies already demonstrated that the pharmacological disinhibition of the sensorimotor, associative, and limbic GPe produced dyskinesia, hyperactivity, and compulsive behaviors, respectively. The aim of this study was to investigate the cortical regions altered by the disinhibition of each GPe functional territory. Thus, 5 macaques were injected with bicuculline in sensorimotor, associative, and limbic sites of the GPe producing dyskinesia, hyperactivity, and compulsive behaviors, and underwent in vivo positron tomography with (18)F-2-fluoro-2-deoxy-D-glucose to identify cortical dysfunctions related to GPe disinhibition...
February 1, 2017: NeuroImage
https://www.readbyqxmd.com/read/27618849/clinical-presentation-of-anxiety-in-parkinson-s-disease-a-scoping-review
#8
Sara G Lutz, Jeffrey D Holmes, Emily A Ready, Mary E Jenkins, Andrew M Johnson
Up to 40% of all individuals with Parkinson's disease (PD) are estimated to experience anxiety that interferes with daily functioning. This article describes research regarding the presentation of anxiety in PD and the influence anxiety has on participation in this population. A scoping review identified 1,635 articles, of which 49 met the inclusion criteria. This review identified that anxiety in PD is often associated with a range of clinical correlates related to demographic and clinical characteristics (age, gender, disease stage, duration, progression), motor symptoms (tremor, bradykinesia, dystonia, freezing of gait, symptom severity), treatment-related complications (on/off fluctuations, on with dyskinesia, unpredictable off), and non-motor symptoms (sleep abnormalities, fatigue, cognitive impairment, depression)...
July 2016: OTJR: Occupation, Participation and Health
https://www.readbyqxmd.com/read/27600559/botulinum-toxin-injection-in-laryngeal-dyspnea
#9
Virginie Woisard, Xuelai Liu, Marie Christine Arné Bes, Marion Simonetta-Moreau
Data, regarding the use of botulinum toxin (BT-A) in laryngeal dyspnea, are scarce, coming from some cases reports in the literature, including Vocal fold paralysis, laryngeal dystonia, vocal cord dysfunction also called paradoxical motion of the vocal fold (PMVF), and post-neuroleptic laryngeal dyskinesia. There is no consensus regarding the muscles and the doses to inject. The aim of this study is to present a retrospective review of patients treated in our ENT Department by BT-A injection in this indication...
February 2017: European Archives of Oto-rhino-laryngology
https://www.readbyqxmd.com/read/27325247/-german-version-of-the-northoff-catatonia-rating-scale-ncrs-dv-a-validated-instrument-for-measuring-catatonic-symptoms
#10
D Hirjak, P A Thomann, G Northoff, K M Kubera, R C Wolf
The clinical picture of catatonia includes impressive motor phenomena, such as rigidity, dyskinesia, festination, negativism, posturing, catalepsy, stereotypies and mannerisms, along with affective (e. g. aggression, anxiety, anhedonism or emotional lability) and behavioral symptoms (e.g. mutism, autism, excitement, echolalia or echopraxia). In English speaking countries seven catatonia rating scales have been introduced, which are widely used in clinical and scientific practice. In contrast, only one validated catatonia rating scale is available in Germany so far...
June 21, 2016: Der Nervenarzt
https://www.readbyqxmd.com/read/27293959/impact-of-sex-on-the-nonmotor-symptoms-and-the-health-related-quality-of-life-in-parkinson-s-disease
#11
Márton Kovács, Attila Makkos, Zsuzsanna Aschermann, József Janszky, Sámuel Komoly, Rita Weintraut, Kázmér Karádi, Norbert Kovács
Background. Female Parkinson's disease (PD) patients seem to experience not only more severe motor complications and postural instability but also more pronounced depression, anxiety, pain, and sleep disturbances. Objective. The aim of the present study was to evaluate the role of sex as a possible independent predictor of HRQoL in PD. Methods. In this cross-sectional study, 621 consecutive patients treated at the University of Pécs were enrolled. Severity of PD symptoms was assessed by MDS-UPDRS, UDysRS, Non-Motor Symptoms Scale, PDSS-2, Hamilton Anxiety Scale, Montgomery-Asberg Depression Rating Scale, Lille Apathy Rating Scale, and Addenbrooke Cognitive Examination...
2016: Parkinson's Disease
https://www.readbyqxmd.com/read/27258695/assessment-of-nonmotor-fluctuations-using-a-diary-in-advanced-parkinson-s-disease
#12
Christiana Ossig, Daniel Sippel, Mareike Fauser, Florin Gandor, Wolfgang H Jost, Georg Ebersbach, Alexander Storch
BACKGROUND: Since previous studies aimed to study nonmotor symptom (NMS) fluctuations in direct conjunction with motor oscillations, there are no data available on the temporal context of NMS fluctuations and motor oscillations in advanced Parkinson's disease (PD). OBJECTIVE: To evaluate circadian patterns and temporal connections of NMS and motor fluctuations in PD. METHODS: 15 controls, 17 non-fluctuating and 15 fluctuating PD patients completed two diaries by rating 4 key psychiatric (anxiety, depressive mood, inner restlessness, concentration/attention deficits), fatigue and 4 autonomic NMS (excessive sweating, sialorrhea, bladder urgency, dizziness) absent or present and motor function (Off, On with/without dyskinesia, and asleep) for every hour for 5 consecutive days...
May 31, 2016: Journal of Parkinson's Disease
https://www.readbyqxmd.com/read/26996632/behavioural-effects-of-basal-ganglia-rho-kinase-inhibition-in-the-unilateral-6-hydroxydopamine-rat-model-of-parkinson-s-disease
#13
Salim Yalcin Inan, Burak Cem Soner, Ayse Saide Sahin
Parkinson's disease (PD) is one of the most common neurodegenerative disorders, which affects more than six million people in the world. While current available pharmacological therapies for PD in the early stages of the disease usually improve motor symptoms, they cause side effects, such as fluctuations and dyskinesias in the later stages. In this later stage, high frequency deep brain stimulation of the subthalamic nucleus (STN-DBS) is a treatment option which is most successful to treat drug resistant advanced PD...
August 2016: Metabolic Brain Disease
https://www.readbyqxmd.com/read/26777085/intraduodenal-levodopa-carbidopa-intestinal-gel-infusion-improves-both-motor-performance-and-quality-of-life-in-advanced-parkinson-s-disease
#14
Florence C F Chang, Vu Kwan, David van der Poorten, Neil Mahant, Nigel Wolfe, Ainhi D Ha, Jane M Griffith, David Tsui, Samuel D Kim, Victor S C Fung
We report the efficacy and adverse effect profile of intraduodenal levodopa-carbidopa intestinal gel (LCIG) infusion from patients treated in a single Australian movement disorder centre. We conducted an open-label, 12 month prospective study of treatment with LCIG in patients with advanced Parkinson's disease in a single tertiary referral hospital unit specialising in movement disorders. Patients with levodopa-responsive, advanced Parkinson's disease with motor fluctuations despite optimal pharmacological treatment were enrolled and underwent a 16 hour daily infusion of LCIG for 12 months...
March 2016: Journal of Clinical Neuroscience: Official Journal of the Neurosurgical Society of Australasia
https://www.readbyqxmd.com/read/26503377/vu0477573-partial-negative-allosteric-modulator-of-the-subtype-5-metabotropic-glutamate-receptor-with-in-vivo-efficacy
#15
Hilary Highfield Nickols, Joannes P Yuh, Karen J Gregory, Ryan D Morrison, Brittney S Bates, Shaun R Stauffer, Kyle A Emmitte, Michael Bubser, Weimin Peng, Michael T Nedelcovych, Analisa Thompson, Xiaohui Lv, Zixiu Xiang, J Scott Daniels, Colleen M Niswender, Craig W Lindsley, Carrie K Jones, P Jeffrey Conn
Negative allosteric modulators (NAMs) of metabotropic glutamate receptor subtype 5 (mGlu5) have potential applications in the treatment of fragile X syndrome, levodopa-induced dyskinesia in Parkinson disease, Alzheimer disease, addiction, and anxiety; however, clinical and preclinical studies raise concerns that complete blockade of mGlu5 and inverse agonist activity of current mGlu5 NAMs contribute to adverse effects that limit the therapeutic use of these compounds. We report the discovery and characterization of a novel mGlu5 NAM, N,N-diethyl-5-((3-fluorophenyl)ethynyl)picolinamide (VU0477573) that binds to the same allosteric site as the prototypical mGlu5 NAM MPEP but displays weak negative cooperativity...
January 2016: Journal of Pharmacology and Experimental Therapeutics
https://www.readbyqxmd.com/read/26455457/new-insight-into-the-therapeutic-role-of-the-serotonergic-system-in-parkinson-s-disease
#16
REVIEW
Yukihiro Ohno, Saki Shimizu, Kentaro Tokudome, Naofumi Kunisawa, Masashi Sasa
Parkinson's disease (PD) is a common, late-onset neurodegenerative disorder that shows progressive extrapyramidal motor disorders (e.g., bradykinesia, resting tremors, muscle rigidity and postural instability) and various non-motor symptoms (e.g., cognitive impairment, mood disorders, autonomic dysfunction and sleep disorders). While dopaminergic agents such as L-3,4-dihydroxyphenylalanine (L-DOPA) and dopamine D2 agonists are widely used for the treatment of PD, there is still high clinical unmet need for novel medications that overcome the limitations of current therapies...
November 2015: Progress in Neurobiology
https://www.readbyqxmd.com/read/26288293/-the-use-of-buspirone-in-clinical-practice
#17
O S Levin
Buspirone, a nonbenzodiasepine anxiolytic, is a partial serotonin 5-HT1A-receptor agonist, D2-autoreceptor antagonist and low affinity 5-HT2-receptor agonist. This medication is used for treatment of generalized anxiety disorder though it may be prescribed in other anxiety states, primarily, panic disorder, sociophobia and depression. Buspirone seems to be potential in treatment of other neurological and mental disorders (tardive dyskinesia in Parkinson's disease, ataxia, behavioral disorders, cranial/brain injuries, dementia, attention-deficit hyperactivity disorder)...
2015: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
https://www.readbyqxmd.com/read/25988034/cognitive-dysfunction-during-anti-nmda-receptor-encephalitis-is-present-in-early-phase-of-the-disease
#18
L Vahter, K Kannel, U Sorro, H Jaakmees, T Talvik, K Gross-Paju
Anti-NMDA-receptor encephalitis is an autoimmune disorder with a well-defined set of clinical features including psychiatric changes (anxiety, agitation, bizarre behaviour, delusional or paranoid thoughts), epileptic seizures and cognitive disturbance followed by movement disorders including orofacial dyskinesias, alterations in the level of consciousness and dysautonomia. Although the cognitive changes are not always very clear at presentation, they can persist after recovery from the acute and often prolonged illness...
July 2014: Oxford Medical Case Reports
https://www.readbyqxmd.com/read/25845678/falls-in-ambulatory-non-demented-patients-with-parkinson-s-disease
#19
MULTICENTER STUDY
Olivier Rascol, Santiago Perez-Lloret, Philippe Damier, Arnaud Delval, Pascal Derkinderen, Alain Destée, Wassilios G Meissner, Francois Tison, Laurence Negre-Pages
This study aimed at determining the prevalence of falling in PD patients, to assess generic and disease-specific clinical and pharmacological factors, relationship with health-related quality of life (HR-QoL) and changes in falls from OFF to ON in patients with motor fluctuations. Six-hundred and eighty-three PD patients of the COPARK survey were evaluated (11 had missing data and were excluded from the analysis). Patients with falls were identified as those with a UPDRS Item 13 ≥ 1 in the ON condition. All patients were assessed in a standardized manner [demographics, treatments, Unified PD Rating Scale (UPDRS), Hospital Anxiety and Depression Scale, Pittsburg questionnaire and HR-QoL scales (SF36, PDQ39)]...
October 2015: Journal of Neural Transmission
https://www.readbyqxmd.com/read/25669730/eltoprazine-counteracts-l-dopa-induced-dyskinesias-in-parkinson-s-disease-a-dose-finding-study
#20
RANDOMIZED CONTROLLED TRIAL
Per Svenningsson, Carl Rosenblad, Karolina Af Edholm Arvidsson, Klas Wictorin, Charlotte Keywood, Bavani Shankar, David A Lowe, Anders Björklund, Håkan Widner
In advanced stages of Parkinson's disease, serotonergic terminals take up L-DOPA and convert it to dopamine. Abnormally released dopamine may participate in the development of L-DOPA-induced dyskinesias. Simultaneous activation of 5-HT1A and 5-HT1B receptors effectively blocks L-DOPA-induced dyskinesias in animal models of dopamine depletion, justifying a clinical study with eltoprazine, a 5-HT1A/B receptor agonist, against L-DOPA-induced dyskinesias in patients with Parkinson's disease. A double-blind, randomized, placebo-controlled and dose-finding phase I/IIa study was conducted...
April 2015: Brain: a Journal of Neurology
keyword
keyword
62671
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"